Breaking Finance News

Spark Therapeutics (NASDAQ:ONCE) stock price target increased to $85.00, released a report earlier today by Leerink Partners

Showing a price of $63.06, Spark Therapeutics (NASDAQ:ONCE) traded -1.15% lower on the day. With the last close up 12.35% from the two hundred day average, compared with the S&P 500 Index which has increased 0.06% over the same period. ONCE has recorded a 50-day average of $58.48 and a two hundred day moving average of $56.69. 244,924 shares of ONCE traded hands, down from an average trading volume of 413,463

Indicating a possible upside of 0.35%, Leerink Partners increased the target of Spark Therapeutics (NASDAQ:ONCE) to $85.00

Performance Chart

Spark Therapeutics (NASDAQ:ONCE)

With a total market value of $0, Spark Therapeutics has with a 52 week low of $24.71 and a 52 week high of $65.99 .

A total of 9 brokers have issued a report on ONCE. zero equity analysts rating the company a strong buy, 5 firms rating the stock a buy, 3 firms rating the company a hold, zero analysts rating the company a underperform, and finally 1 broker rating the stock a sell with a average stock price target of $58.44.

General Information About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington's disease, a hereditary genetic disorder.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.